Table 3.

Germline TP53 testing in Women with Breast Tumour.

Age of Breast Tumour Onset	Presentation
When TP53 testing should systematically be performed
Before 31	Invasive breast carcinoma a or ductal carcinoma in situ (DCIS)
Before 36	–Bilateral invasive breast carcinoma or DCIS –or Multifocal invasive breast carcinoma or DCIS –or HER2+ invasive breast carcinoma or DCIS –Phyllode tumour
Before 46	–Invasive breast carcinoma and a second TP53 core tumour in the patient a –or invasive breast carcinoma and one first- or second-degree relative with a TP53 core tumour before 56 years a,b
When TP53 testing may be offered
Before 46	–Bilateral invasive breast carcinoma –or HER2+ invasive breast carcinoma and a familial history of HER2+ breast cancer
When TP53 testing should not be performed
After 46	No previous TP53 core tumour before 46 and no familial history fulfilling Chompret criteria

^a Chompret criteria (14), ^b TP53 core tumour: breast cancer, soft-tissue sarcoma, osteosarcoma, central nervous system tumour, adrenocortical carcinoma. DCIS: ductal carcinoma in situ.